Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881166 · ClinicalTrials.gov registry record · Phase 1
Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT00881166 is a Phase 1 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 101 participants.
The verdict
NCT00881166, a Phase 1 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm. Primary objective: Determine the MTD. Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with specific SOC treatments.
Interventions
- DRUG MP-470 + topotecan
- DRUG MP-470 + docetaxel
- DRUG MP-470 + erlotinib
- DRUG MP-470 + paclitaxel/carboplatin
- DRUG MP-470 + carboplatin/etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881166
The ClinicalTrials.gov registry entry for NCT00881166 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MP-470 + topotecan is the first listed.
NCT00881166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00881166 about?
NCT00881166 is a clinical study titled "Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors". Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm. Primary objective: Determine the MTD. Secondary objectives: Respons...
What is the current status of trial NCT00881166?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2007-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00881166?
The interventions under investigation include: MP-470 + topotecan (DRUG), MP-470 + docetaxel (DRUG), MP-470 + erlotinib (DRUG), MP-470 + paclitaxel/carboplatin (DRUG), MP-470 + carboplatin/etoposide (DRUG).
Who is sponsoring clinical trial NCT00881166?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.